ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

STIM Neuronetics Inc

1.73
-0.04 (-2.26%)
25 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neuronetics Inc NASDAQ:STIM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.04 -2.26% 1.73 1.68 1.90 1.79 1.70 1.76 148,571 22:59:00

Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference

23/05/2024 1:30pm

GlobeNewswire Inc.


Neuronetics (NASDAQ:STIM)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Neuronetics Charts.

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.

Investor Contact:

Mike Vallie or Mark KlausnerICR Westwicke443-213-0499ir@neuronetics.com

Media Contact:

EvolveMKD646-517-4220NeuroStar@evolvemkd.com

1 Year Neuronetics Chart

1 Year Neuronetics Chart

1 Month Neuronetics Chart

1 Month Neuronetics Chart